Here are 19 key notes on orthopedic and spine device companies over the past week.
Mazor Robotics reported $8.3 million generated revenue in the second quarter of 2016.
Dennis P. Devito, MD, and Kornelis Poelstra, MD, will host a webinar on their experiences using Mazor Robotics technology.
K2M reported its total revenue was $59.2 million for the second quarter of 2016, up 5.1 percent compared to the same period the year prior.
Xtant Medical's second quarter revenue was approximately $21.5 million, down slightly from pro forma revenue of around $21.6 million for the same period during 2015.
Xtant Medical is expanding its tissue processing facility in Belgrade, Mont.
Smith & Nephew reported a 2 percent revenue increase in the second quarter of 2016.
Integra LifeSciences' revenue hit $249.3 million in the second quarter, an increase of 17.2 percent over the same period in 2015.
Orthofix's BioStim segment was a primary driver in the company's net sales growth in the second quarter.
Corin Group signed an expanded distribution agreement with FX Solutions.
Surgeons have implanted more than 10,000 of Carlsbad, Calif.-based Spinal Elements' Ti-Bond interbody devices in patients.
Surgeons have used Vertical Spine's FIBRINET System technology in 1,000 cases.
Amendia is expanding its manufacturing facility in Marietta, Ga.
NuVasive recently announced the appointment of two members to its board of directors — Mike O'Halleran and Pat Miles.
Zimmer Biomet and Stryker lead the $2 billion-Asia Pacific large joint replacement device market.
DePuy Synthes can now help hospitals address CMS' newly implemented mandatory coordinated care/episode payment programs through its Geriatric Future Program.
Flower Orthopedics launched its new MTP Fusion Plate Portfolio.
DePuy Synthes Trauma launched the Variable Angle Locking Hand System.
Cesca Therapeutics released the study results on its technology for treating non-union fractures that shows bone marrow concentrate is an effective treatment.
Mesoblast announced the 24-month results from its chronic low back pain product trial — the 100-patient randomized Phase 2 trial tested the company's allogenic mesenchymal precursor cells.